The 2025-2030 World Outlook for Anti-Migraine Drugs - Image 1

Out of stock

This item is currently unavailable

The 2025-2030 World Outlook for Anti-Migraine Drugs

Subjects

Out of stock

Price data last checked 15 day(s) ago - will refresh soon

View at Amazon

One email. No newsletter. No nudges.

Out of stock for 15 days. The last 3 returns each lasted under a day — get on the list.

Out of stock 15 days · usually back within 14 days

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

No price data yet

Price history will appear here once data is collected from Amazon.

Price Distribution

No price data available for histogram

Description

This study covers the world outlook for anti-migraine drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of anti-migraine drugs as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, Alder BioPharmaceuticals, Allergan, Amgen, Biohaven Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Kowa Pharmaceuticals America, Merck & Company, Novartis, Otsuka Pharmaceutical Company, Pfizer, and Teva Pharmaceutical Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).

Product Specifications

Format: paperback
ASIN: B0CYDNMQV4
Category: Books > Subjects
Domain: Amazon UK
Release Date: 03 March 2024
Listed Since: 04 April 2024

The 2025-2030 World Outlook for Anti-Migraine Drugs

Out of stock for 15 days. The last 3 returns each lasted under a day — get on the list.

Price History & Forecast

Price Distribution

Description

Product Specifications

Similar Products You Might Like

The 2021-2026 World Outlook for Anti-Migraine Drugs

The 2023-2028 Outlook for Anti-Migraine Drugs in China

The 2023-2028 Outlook for Anti-Migraine Drugs in the United States

The 2023-2028 World Outlook for Acute-Treatment Migraine Drugs

The 2016-2021 Outlook for Anti-Migraine Drugs in Europe

The 2023-2028 Outlook for Anti-Migraine Drugs in Japan

The 2016-2021 Outlook for Anti-Migraine Drugs in Asia

The 2016-2021 Outlook for Anti-Migraine Drugs in North America & the Caribbean

The 2016-2021 Outlook for Anti-Migraine Drugs in Latin America

The 2023-2028 Outlook for Anti-Migraine Drugs in India

The 2013-2018 Outlook for Anti-Migraine Drugs in Europe & the Middle East

The 2016-2021 Outlook for Anti-Migraine Drugs in Oceana

The 2016-2021 Outlook for Anti-Migraine Drugs in Africa & the Middle East

The 2013-2018 Outlook for Anti-Migraine Drugs in Africa

The 2016-2021 Outlook for Anti-Migraine Drugs in the United States

The 2016-2021 Outlook for Anti-Migraine Drugs in Greater China

The 2011-2016 Outlook for Anti-Migraine Drugs in The Middle East

The 2023-2028 Outlook for Anti-Migraine Drugs for US Zip Codes

The 2016-2021 Outlook for Anti-Migraine Drugs in India

The 2016 Report on Anti-Migraine Drugs: World Market Segmentation by City

Traitements de crise et traitements de fond de la migraine: Aspects pharmacothérapeutiques (Omn.Univ.Europ.)

Springer - Migraine and Headache Disorders Global Perspective

Academic Press - Interventional Management of Migraines

Migraine Biology, Diagnosis, and Co-Morbidities (Volume 198) (Handbook of Clinical Neurology, Volume 198)